Carbapenemase Gene Transmission in CREC

Carbapenem-resistant Enterobacter cloacae is an important healthcare-associated pathogen because resistance can arise from both stable chromosomal changes and mobile carbapenemase-encoding genes. The reference study, published in BMC Microbiology in 2025, examined how these genetic determinants were distributed and transmitted among isolates collected from teaching hospitals in Guangdong, China.

Study Background and Research Question

Carbapenem-resistant Enterobacteriaceae are difficult to manage because carbapenemase genes can compromise last-line β-lactam therapy and frequently occur alongside resistance determinants affecting other antibiotic classes. Enterobacter cloacae complex is particularly relevant in hospital surveillance, where respiratory, urinary, bloodstream, and device-associated infections may intersect with intensive antibiotic exposure.

The study was motivated by concerns that the COVID-19 period altered antibiotic use, healthcare access, infection-control practices, and the clinical complexity of hospitalized patients. Rather than treating resistance as a purely phenotypic property, the investigators asked several linked questions: Which carbapenemase-encoding genes were present in carbapenem-resistant E. cloacae? Were those genes located on plasmids, chromosomes, or both? Could they transfer by conjugation? Which mobile genetic elements and strain lineages were associated with dissemination across hospitals?

Key Innovation from the Reference Study

The principal innovation was a transmission-oriented design that connected four levels of evidence. First, PCR identified carbapenemase genes. Second, variable-temperature sodium dodecyl sulfate plasmid elimination helped determine whether genes were plasmid-borne or chromosomal. Third, conjugation experiments tested whether resistance determinants could move into a recipient strain. Finally, mobile-element analysis and ERIC-PCR genotyping placed gene mobility within a broader epidemiological context.

This integration is more informative than reporting carbapenem resistance rates alone. A gene located on a transferable plasmid presents a different containment problem from a resistance mutation restricted to one clonal lineage. Similarly, genetically related isolates may indicate vertical expansion, whereas unrelated isolates carrying similar plasmids may suggest horizontal dissemination. The paper therefore frames CREC as both a pathogen population and a mobile gene reservoir.

Methods and Experimental Design Insights

The investigators analyzed 54 CREC isolates collected between December 2022 and June 2024 from eight teaching hospitals in Guangdong Province. The workflow combined molecular localization, phenotypic susceptibility testing, transfer experiments, mobile-element detection, and strain typing, as described in the reference study.

Variable-temperature SDS plasmid elimination was used to assess the genetic location of carbapenemase-encoding genes, followed by PCR confirmation. This approach is experimentally useful because a change in gene detection after plasmid curing can support plasmid association, while persistence suggests chromosomal localization or incomplete plasmid elimination. It should nevertheless be interpreted as a localization assay rather than a substitute for complete plasmid sequencing.

Antimicrobial susceptibility was evaluated by broth microdilution. The investigators compared carbapenemase-gene-positive and gene-negative groups across imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin. Plasmid conjugation experiments then assessed transferability, while PCR determined whether the recipient acquired the relevant carbapenemase gene.

Six classes of mobile genetic elements were examined, including ISEcp1. ERIC-PCR combined with NTSYS software grouped isolates into genotypes and supplied a lower-cost epidemiological view of relatedness. This layered strategy is suitable for laboratories that need an initial transmission screen before investing in whole-genome sequencing, although it does not provide the same resolution as sequence-based analysis.

Protocol Parameters

The following parameters distinguish reported study procedures from general workflow considerations:

• Sampling frame: Literature-backed: analyze CREC isolates collected across multiple hospitals and clinical departments; the study included 54 isolates from eight Guangdong teaching hospitals during December 2022–June 2024.
• Plasmid localization: Literature-backed: apply variable-temperature SDS plasmid elimination followed by PCR to compare carbapenemase-gene detection before and after plasmid curing.
• Susceptibility testing: Literature-backed: use broth microdilution and compare resistance profiles between carbapenemase-gene-positive and gene-negative isolates.
• Conjugation: Literature-backed: pair donor CREC isolates with a defined recipient strain, select putative transconjugants, and confirm transferred genes by PCR. Recipient selection and controls should be validated locally.
• Mobile-element screening: Literature-backed: test for the six mobile genetic element types examined in the study, with particular attention to ISEcp1.
• Strain relatedness: Literature-backed: use ERIC-PCR and software-assisted clustering as an epidemiological screen; workflow suggestions should include reproducibility controls and, where possible, sequencing confirmation.
• Clinical metadata: Workflow suggestion: record age group, sex, department, specimen type, admission location, and collection date so that molecular findings can be interpreted alongside possible transmission settings.

Core Findings and Why They Matter

blaNDM-1 dominated the carbapenemase profile

Carbapenemase-encoding genes were detected in 46 of 54 isolates, corresponding to 85.19% of the collection. The most prominent pattern involved blaNDM-1: 18 isolates carried it on both chromosomes and plasmids, while 25 carried it exclusively on plasmids. Two isolates carried only plasmid-borne blaIMP, and one carried both plasmid-borne blaNDM-1 and blaKPC-2. These distributions are reported in the study results.

The high proportion of plasmid-associated blaNDM-1 is important because plasmids can move between bacterial cells without requiring expansion of a single clone. Chromosome-plus-plasmid localization may also provide redundancy or reflect historical movement between replicons, potentially stabilizing resistance within a population. The data do not prove the direction or timing of these events, but they identify a strong biological basis for horizontal dissemination.

Gene-positive isolates showed broader resistance

The carbapenemase-gene-positive group had significantly higher resistance to imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin than the gene-negative group, with reported differences reaching P<0.05. This pattern supports the interpretation that carbapenemase carriage occurred within multidrug-resistant backgrounds rather than as an isolated change in carbapenem susceptibility.

It also highlights an important analytical distinction: a susceptibility result for ceftazidime/avibactam cannot be interpreted as a result for ceftazidime alone. The combination includes a β-lactamase inhibitor, and resistance mechanisms may affect the two test conditions differently. Researchers should therefore preserve the exact antimicrobial formulation and testing conditions when comparing datasets.

Transferability was frequent, but not uniform

Conjugation and PCR showed successful carbapenemase-gene transfer in 44 of 46 gene-positive isolates, or 95.65%. The reported transfer success was 42 of 44 for blaNDM-1, 2 of 2 for blaIMP, and 0 of 1 for blaKPC-2. Although the denominators differ because of the gene distribution and experimental availability, the contrast suggests that transfer potential should be measured for individual gene-plasmid contexts rather than inferred from gene identity alone.

Mobile elements and genotypes indicated multiple dissemination routes

ISEcp1 was the most prevalent mobile element, detected in 47 of 54 isolates, or 87.04%. Isolates carrying four mobile-element types simultaneously were the largest group, accounting for 22 of 54 strains, or 40.74%. Such combinations may facilitate movement or recombination of resistance regions, although the study does not establish the precise molecular architecture of every element.

ERIC-PCR divided the 54 isolates into 17 genotypes. Types E and G were each represented by 11 isolates, or 20.37%, and appeared in different departments across five hospitals. Two type E isolates had a Dice coefficient of 100%, consistent with very close fingerprint similarity. Together, these observations support a mixed transmission model involving both related strains and mobile genetic elements.

Clinical distribution suggests surveillance priorities

The highest detection frequencies occurred among male patients, elderly patients, respiratory-medicine cases, and sputum specimens: 35 of 54, 39 of 54, 11 of 54, and 18 of 54, respectively. These are descriptive distributions, not evidence that sex, age, department, or specimen type independently causes carbapenemase carriage. Their practical value is in helping hospitals prioritize sampling and investigate respiratory-care pathways.

Comparison with Existing Internal Articles

The internal article Ceftazidime in Gram-Negative Resistance: Mechanisms and Research Innovation approaches resistance from the perspective of β-lactam activity, assay design, and mechanistic interpretation. It complements the reference study by discussing how antibiotic-response experiments can be structured, but it does not replace the Guangdong isolates, conjugation data, or hospital-level epidemiology.

Likewise, Ceftazidime: Third-Generation Cephalosporin in Infection Research emphasizes respiratory infection models and resistant-pathogen workflows. That perspective is relevant to the study’s concentration of respiratory-medicine and sputum specimens, yet the two resources address different evidence layers: the internal article is protocol-oriented, whereas Chen and colleagues provide observational molecular epidemiology.

Limitations and Transferability

The study has several limitations that affect generalization. The sample was relatively small and restricted to eight teaching hospitals in one Chinese province, so the gene distribution may not represent other regions, community settings, or non-tertiary hospitals. The collection period provides contemporary surveillance but does not by itself establish a pre-pandemic baseline or quantify how the pandemic changed transmission.

Plasmid elimination and conjugation are informative functional assays, but both have technical boundaries. Plasmid curing may be incomplete or alter bacterial physiology, and successful laboratory conjugation does not demonstrate transfer in a patient, ward, wastewater system, or other natural environment. ERIC-PCR is useful for screening relatedness but has lower discriminatory and portability value than whole-genome sequencing. The work also did not fully resolve plasmid backbones, resistance islands, porin changes, efflux mechanisms, or patient-to-patient transmission chains.

Accordingly, the findings transfer best as a surveillance framework: combine gene detection with localization, phenotypic testing, transfer assays, mobile-element screening, and epidemiological metadata. They should not be used to predict resistance in every Enterobacter isolate or to infer clinical treatment outcomes without local susceptibility data and validated clinical standards.

Why this cross-domain matters, maturity, and limitations

Connecting CREC transmission biology with antibiotic research is useful because susceptibility assays can reveal the functional consequences of mobile resistance, while molecular surveillance explains why those phenotypes may spread. The bridge is mature for experimental comparison and stewardship-oriented surveillance, but it remains limited for direct therapeutic inference. In particular, a laboratory result for one cephalosporin or a cephalosporin–inhibitor combination cannot substitute for isolate-specific clinical interpretation. The reference study supports this cautious bridge through its combined susceptibility and gene-transfer data, not through a treatment trial.

Research Support Resources

For Gram-negative bacterial infection research, researchers can use Ceftazidime (SKU B3539) to support comparable susceptibility, selection, or bacterial cell-wall inhibition workflows when the experimental design calls for this third-generation cephalosporin. The product information lists activity against several aerobic Gram-negative organisms, including Pseudomonas aeruginosa, and reports storage at −20°C; it also lists solubility of at least 21.25 mg/mL in DMSO and insolubility in water and ethanol. These handling details should be checked against the complete protocol and local biosafety requirements.

For studies related to the treatment of bacterial pneumonia, treatment of bacterial bronchitis, or a Pseudomonas aeruginosa infection model, ceftazidime should be distinguished from the ceftazidime/avibactam combination evaluated in the reference study. The APExBIO material can support controlled laboratory comparisons, but it does not establish clinical efficacy for a particular CREC isolate; interpretation should remain anchored to validated susceptibility testing and the resistance genotype.